Artificial intelligence accounting automation platform startup Numeric has raised $51 million in new funding to expand from close management into a broader compound startup model that delivers a ...

In the first-line treatment of higher-risk myelodysplastic syndromes (MDS), the combination of venetoclax with azacitidine fell short of the primary endpoint of a reduction in mortality compared with ...

The new 770 is a perfect example of how New Balance Numeric is approaching skate footwear with a more “intelligent” design philosophy. It takes a classic, long-retired silhouette and infuses it with ...

Racial and Ethnic Disparities in Receipt of Guideline-Concordant Pancreatic Cancer Care Among Older Adults in the United States Myelodysplastic syndromes (MDS) are a heterogeneous group of diseases ...

For Medicare patients, surgical outcomes were similar whether they had an MD or a DO surgeon, a claims analysis suggested. After adjusting for patient factors and practice settings, there was no ...

Microsoft today announced an artificial intelligence tool that outperformed a panel of medical doctors in diagnosing complicated cases. The Microsoft AI Diagnostic Orchestrator (MAI-DxO) faced off ...

The blood cancers acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are extremely challenging to treat. While advances in immunotherapy have cured many patients with other blood cancers, ...

There are more treatments today than ever before to help people with ongoing conditions manage their physical symptoms. But even with these medical advances, a diagnosis of myelodysplastic syndromes ...

fix: Feedback addressed by @arturoboquin suggested by @Marcony1 (75f7990) fix: Feedback addressed by @arturoboquin suggested by @Marcony1 (5acb30c) fix: Feedback addressed by @arturoboquin suggested ...

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for high-risk myelodysplastic syndrome, leading to the trial being discontinued. In ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies ...

Approximately half of the patients with MDS who responded to treatment with Rytelo went a year without needing a blood transfusion, one expert explained. The approval by the Food and Drug ...